Latest news about Sakar Healthcare
Sakar Healthcare
696.70
+96.90(+16.16%)
Company Performance:
View Company Insights1D+16.16%
1M+12.63%
6M+76.40%
1Y+124.20%
5Y+421.68%
More news about Sakar Healthcare
19Dec 25
Sakar Healthcare Secures European Oncology Deal
Sakar Healthcare has entered into a strategic supply agreement with Accord to distribute Imatinib tablets (100mg and 400mg) in European markets. This deal marks the first of nine planned oncology products in their partnership, signaling Sakar's expansion into the European oncology market and demonstrating its manufacturing capabilities and regulatory compliance with European standards.
19Dec 25
Sakar Healthcare Secures European Supply Contract Following EU Approval for Imatinib Tablets
Sakar Healthcare has been designated as the supplier for Imatinib tablets to the European market following Accord Healthcare's successful EU approval for 100 MG and 400 MG dosage strengths. This supply arrangement expands Sakar Healthcare's presence in the European pharmaceutical sector, potentially boosting sales performance and demonstrating the company's ability to meet international regulatory standards.
06Nov 25
Sakar Healthcare Expands Cancer Treatment Portfolio with Nine New Authorizations
Sakar Healthcare has secured nine new marketing authorizations for cancer products across Europe and emerging markets, bringing their total to eleven. The approvals include key medications such as Carboplatin, Docetaxel, and Tamoxifen, which are used in treating various types of cancers. This expansion strengthens Sakar's position in the global cancer treatment market and may increase accessibility to critical cancer medications in various regions.
25Jul 25
Sakar Healthcare Reports 95% Surge in Q1 Net Profit, EBITDA Grows Despite Margin Decline
Sakar Healthcare Ltd. announced impressive Q1 results with net profit soaring 95% to ₹46.70 million from ₹24.00 million year-over-year. EBITDA grew 18.7% to ₹127.00 million, although EBITDA margin slightly decreased to 24.1% from 26.0%. The company demonstrated strong profitability growth despite some margin pressure, indicating effective cost management and possibly a favorable product mix.
16Jul 25
Sakar Healthcare Expands European Footprint with New Anti-Cancer Injection Approvals
Sakar Healthcare Ltd. has obtained its third and fourth marketing authorizations for oncology injections in the European market. The company is now preparing for commercial supply of these newly approved products, potentially opening up new revenue streams and strengthening its position in the oncology sector. This expansion into the European market with specialized oncology products is expected to diversify the company's market presence, offer revenue growth potential, and enhance its global standing in the pharmaceutical industry.
18Jun 25
Sakar Healthcare Eyes EU Expansion with Anticipated MAS Approval for Oncology Products
Sakar Healthcare Ltd expects to receive Marketing Authorization System (MAS) approval for its oncology products in the European Union (EU) over the coming months. The company has already secured its second marketing authorization for an oncology injection in the EU. These approvals are expected to significantly boost Sakar's export capabilities to the EU market, potentially increasing its global footprint and revenue streams. The gradual approval process reflects the company's strategic focus on the oncology segment and its efforts to expand in the European pharmaceutical market.
15May 25
Sakar Healthcare Reports Impressive Q4 FY23 Results with Substantial Profit Growth
Sakar Healthcare Ltd has released its Q4 FY23 financial results, showing significant year-over-year improvements. Net profit increased by 87.10% to ₹58.00 crore, while revenue grew by 16.74% to ₹502.00 crore. EBITDA rose by 42.73% to ₹157.00 crore, with the EBITDA margin expanding by 583 basis points to 31.30%. These results demonstrate strong performance across all key financial metrics, indicating robust demand for the company's products and improved operational efficiency.
21Apr 25
Sakar Healthcare Achieves First EU Marketing Authorization for Oncology Injection
Sakar Healthcare Ltd has obtained its first Marketing Authorization (MA) in the European Union for an oncology injection. This approval marks a significant milestone in the company's international expansion, opening up opportunities in the European oncology market. The authorization demonstrates Sakar's ability to meet EU regulatory standards and strengthens its oncology product portfolio.
16Apr 25
Sakar Healthcare Expands Global Reach with 9 New Export Agreements
Sakar Healthcare Ltd has signed nine strategic agreements with partners in Europe and South America for exporting oncology products. This move marks a significant step in the company's global expansion strategy, particularly in the oncology segment. While financial details are undisclosed, the partnerships are expected to boost export volumes and revenue, diversify market presence, and strengthen the company's position in the specialized pharmaceutical market.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,878.20
(+0.81%)
6,760.50
(-2.33%)
4,405.70
(+0.04%)
1,432.10
(-0.32%)
1,336.70
(+2.54%)
2,276.20
(+0.80%)
2,503.00
(+1.66%)
1,011.70
(+2.02%)
1,511.80
(+0.06%)
1,323.60
(+0.62%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
